Japan Renal Cancer Drugs Market Analysis

Japan Renal Cancer Drugs Market Analysis


$ 3999

Japan Renal Cancer Drugs Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. Renal Cancer Drugs market is growing globally due to the increasing incidences of kidney diseases and renal cancer, increased demand for immunotherapies, research and development spending on new drug development, growing aging population, increasing healthcare expenditure and favorable reimbursement policies for renal cancer drugs. Pfizer Inc, AstraZeneca, Bristol-Myers Squibb Company, Dr. Reddy's Laboratories Ltd, Endo International plc, Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, Mylan N.V., Novartis AG, Lupin, Cipla Inc, Aurobindo Pharma, Fresenius SE & Co. KGaA, Sanofi, Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd, Abbott are the key global market players in renal cancer drugs market.

ID: IN10JPPH390 CATEGORY: Pharmaceuticals GEOGRAPHY: Japan AUTHOR: Dr. Medha Sansanwal

Buy Now

Japan Renal Cancer Drugs Market Analysis Summary

Japan Renal Cancer Drugs Market is valued at around $384.8 Mn in 2022 and is projected to reach $622.6 Mn by 2030, exhibiting a CAGR of 6.2% during the forecast period 2023-2030.

Renal cancer, also known as kidney cancer, is a disease characterized by the development of malignant tumors in the kidneys. Common symptoms include blood in urine, back or flank pain, mass or lump in the abdomen, fatigue, loss of appetite, unintentional weight loss, and loss of appetite. Treatment of this disease includes targeted therapies that target specific molecules or pathways involved in the growth and spread of cancer cells like sunitinib, pazopanib, and axitinib. Immunotherapies are drugs that work by enhancing the body’s immune system like nivolumab, pembrolizumab, and nivolumab. Chemotherapy drugs like gemcitabine and cisplatin and surgery can be performed for localized renal cancer. Pfizer Inc, AstraZeneca, Bristol-Myers Squibb Company, Dr. Reddy's Laboratories Ltd, Endo International plc, Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, Mylan N.V., Novartis AG, Lupin, Cipla Inc, Aurobindo Pharma, Fresenius SE & Co. KGaA, Sanofi, Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd, Abbott are the key global market players in renal cancer drugs market.

Market Dynamics

Market Growth Drivers

Increasing incidences of kidney diseases and renal cancer, increased demand for immunotherapies, research and development spending on new drug development, growing aging population, increasing healthcare expenditure, and favorable reimbursement policies for renal cancer drugs. All these factors act as market growth drivers.

Market Restraints

High cost of treatment, limited treatment options for advanced stages, side effects of kidney cancer drugs such as loss of appetite, fever, rashes, patent expirations, generic drug competition, lack of awareness, and early diagnosis. All these factors act as market growth restraints.

Competitive Landscape

Key Players

  • Pfizer Inc
  • AstraZeneca
  • Bristol-Myers Squibb Company
  • Dr. Reddy's Laboratories Ltd
  • Endo International plc
  • Teva Pharmaceutical Industries Ltd
  • Sun Pharmaceutical Industries Ltd
  • Mylan N.V.
  • Novartis AG
  • Lupin
  • Cipla Inc
  • Aurobindo Pharma
  • Fresenius SE & Co. KGaA
  • Sanofi
  • Takeda Pharmaceutical Company Limited
  • F. Hoffmann-La Roche Ltd
  • Abbott

Notable Deals in the Renal Cancer Drugs Market

In 2022, the clinical hospital of the faculty of medicine of Ribeiro Preto teamed with Bristol Myers Squibb and the So Paulo Research Foundation for the introduction of Nivolumab, a brand-new medication for kidney cancer. It is in Phase 2 clinical trial.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Market Segmentations For Japan Renal Cancer Drugs Market

By Type

  • Renal Cell Carcinoma (RCC)
  • Papillary Renal Cell Carcinoma
  • Chromophobe Renal Cell Carcinoma
  • Unclassified Renal Cell Carcinoma
  • Transitional Cell Carcinoma
  • Wilms Tumor (Nephroblastoma)
  • Renal Sarcoma
  • Angiomyolipoma
  • Oncocytoma
  • Others

By Drug Class

  • Monoclonal Antibodies
  • mTOR Inhibitors
  • Immune Checkpoint Inhibitor
  • Combined Therapies
  • Interleukin-2
  • Alpha-Interferon
  • Others

By End-Users

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.​

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

  • Analyzing historical proprietary data collected from multiple projects.
  • Regularly updating our existing data sets with new findings and trends.
  • Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

  • Searching through academic conferences, published research, citations, and social media platforms
  • Collecting and compiling diverse data to build a comprehensive and detailed database
  • Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

  • Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
  • Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
  • Continuously refreshing our database to ensure that the information remains current and reliable.
  • Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

  • Merging historical data from secondary research with real-time data from primary research.
  • Conducting thorough data validation and cleansing to remove inconsistencies and errors.
  • Organizing data into a structured format that is easily accessible and usable for various applications.
  • Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.

To request a free sample copy of this report, please complete the form below.


We value your inquiry and offer free customization with every report to fulfil your exact research needs.


Last updated on: 27 February 2024
Updated by: Anish Swaminathan

Related reports (by category)


Related reports (by geography)


subscribe to our newsletter
up